


## SUPPLEMENTARY FIGURES:


**Supplementary Fig. 1:** (A) CD11b<sup>+</sup>Gr1<sup>-</sup> and (B) CD11b<sup>+</sup>Gr1<sup>+</sup> myeloid cells isolated from pancreata of clodronate- or PBS-liposome-treated KPC mice were determined by flow cytometry after gating on live CD45<sup>+</sup> cells. Graph represents the mean percentage  $\pm$  SD of CD11b<sup>+</sup>Gr1<sup>-</sup> and CD11b<sup>+</sup>Gr1<sup>+</sup> cells among total CD45<sup>+</sup> cells. Dots represent data from each animal; *black horizontal lines*, the mean percentage for each group. \*p=0.0164 by Mann-Whitney-U-Test. (C) Emr1 mRNA (F4/80 antigen) determined by qRT-PCR in lungs from clodronate- or PBS-liposome-treated mice, normalized to the ribosomal protein RPLP0 as internal standard. Data are shown as mean  $\pm$  SD. \*p=0.035 by Mann-Whitney-U-Test.

Suppl. Figure 1




**Supplementary Fig.2:** (A) Determination of tumour volume in the tumour-bearing mice of both cohorts, presented as mean  $\pm$  SD. One dot represents data from each animal; *black horizontal line*, the mean percentage for each group. ns = not significant by Mann-Whitney-U-Test,  $p > 0.05$ . (B) Classification and distribution of PanIN lesions (PanIN I-III) in the animals without a PDAC. Data are not significant by Fisher's exact test,  $p > 0.05$ . (C) Tumour differentiation grade. Mean percentage of animals with grade G3 or G4 (sarcomatoid) tumour. Data are not significant between clodronate- or PBS-liposomes by Fisher's exact test,  $p > 0.05$ .

Suppl. Figure 2




**Supplementary Fig.3:** (A) Quantification of number of metastases in H&E stained whole lung sections from each clodronate- (n=8) and PBS-Liposome (n=7) treated non-transgenic WT animal. Data are shown represent mean  $\pm$  SD. Symbols: ns = not significant.

Suppl. Figure 3




**Supplementary Fig.4:** Representative analysis of M1 markers  $Tnf\alpha$  and  $Cxcl10$  (A) and the M2 markers  $Ym1$  and  $Mrc1$  (B) in isolated primary bone marrow-derived macrophages stimulated by LPS,  $IFN\gamma$ , LPS/ $IFN\gamma$  as M1- and by IL4 as M2-polarising cytokines. Quantitative RT-PCR was normalized to the ribosomal protein RPLP0 as internal standard.

Suppl. Figure 4




**Supplementary Fig.5:** (A) Phagocytosis assay: M1- and M2-polarised macrophages were incubated with FITC-conjugated latex beads for indicated time points at 4 and 37°C and uptake of fluorescence latex beads per macrophage was analyzed by flow cytometry. Data shown as mean  $\pm$  SD normalized to phagocytosis of macrophages incubated at 4°C. Experiment was done in triplicates. (B) Representative flow cytometry profile of internalized fluorescence latex beads of M1 and M2 macrophages incubated at 4 or 37°C. Symbols: ns = not significant; \*p=0.015 by Mann-Whitney-U-Test.

Suppl. Figure 5




**Supplementary Fig.6:** Quantitative densitometry of the Western blots shown in figure 5C-F depicting VEGF protein levels in the liver (A) and serum (B) of KPC mice after clodronate- or PBS-liposome treatment; in bone marrow-derived macrophages from non-transgenic animals after clodronate- or PBS-liposome treatment (C); and in the serum of DT- or PBS-treated KPCD mice (D). Data represent three densitometries and were normalized to the intensity of actin bands. Arbitrary units (AU) are expressed as mean  $\pm$  SD. ns = not significant, \* $p < 0.05$ , \*\* $p < 0.008$ , \*\*\* $p < 0.0001$  by Mann-Whitney-U-Test.

Suppl. Figure 6




**Supplementary Fig.7:** Percentage of CD11b<sup>+</sup>Gr1<sup>-</sup> (A) and CD11b<sup>+</sup>Gr1<sup>+</sup> (B) myeloid cells from pancreata, livers, spleen and blood of DT (grey triangle, n=4) or PBS (black rhomb, n=4) treated KPCD mice were evaluated by flow cytometry after gating on CD45<sup>+</sup> cells. Data shown as mean  $\pm$  SD. Symbols: dots represent data from each animal; *black horizontal line*, mean percentage for each group. ns = not significant, \*p =0.014, \*\*p<0.004 by Mann-Whitney-U-Test.

Suppl. Figure 7



**Supplementary Fig.8:** The M1 marker Cxcl10 and the M2 marker Mrc1 were quantified in liver (A, B) and lung (C, D) tissues of DT or PBS treated KPCD animals (n=4 DT, n=4 PBS) by qRT-PCR and were normalized to RPL0. Data are shown as mean  $\pm$  SD. Symbols: ns = not significant; \*p=0.0201 by Mann-Whitney-U-Test.

Suppl. Figure 8



**Supplementary Fig.9:** CD4<sup>+</sup>CD25<sup>+</sup> T cells from pancreata (A), liver (B) and blood (C) of clodronate- or PBS-liposome-treated KPC mice were quantified by flow cytometry after gating on live CD45<sup>+</sup>CD3<sup>+</sup> cells. Graphs represent the mean  $\pm$  SD of CD4<sup>+</sup>CD25<sup>+</sup> T cells among total CD45<sup>+</sup>CD3<sup>+</sup> cells. Dots represent data from each animal; *black horizontal lines*, the mean percentage for each group. ns = not significant by Mann-Whitney-U-Test. (D) CD4<sup>+</sup>CD25<sup>+</sup> cells isolated from spleen of WT mice (n=3) were activated and subsequently treated with clodronate- or PBS-liposomes for 24 hours. Assay was performed in triplicate and cell viability was determined by ATP-based CellTiter Glo assay. Data are shown as mean  $\pm$  SD and are representative of three independent experiments. Symbols: ns = not significant by Mann-Whitney-U-Test.

Suppl. Fig.9

